Learn More
Advances in deep brain stimulation (DBS) therapeutics for neurological and psychiatric disorders represent a new clinical avenue that may potentially augment or adjunct traditional pharmacological approaches to disease treatment. Using modern molecular biology and genomics, pharmacological development proceeds through an albeit lengthy and expensive(More)
UNLABELLED Following the discovery of the antidepressant properties of ketamine, there has been a recent resurgence in the interest in this NMDA receptor antagonist. Although detailed animal models of the molecular mechanisms underlying ketamine's effects have emerged, there are few MEG/EEG studies examining the acute subanesthetic effects of ketamine(More)
  • 1